Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction - The OACIS-LIPID study

Circulation Journal

Volumn 72, Issue 1, 2008, Pages 17-22

  Sato, Hiroshi ^a   Kinjo, Kunihiro ^a   Ito, Hiroshi ^b   Hirayama, Atsushi ^c   Nanto, Shinsuke ^d   Fukunami, Masatake ^e   Nishino, Masami ^f   Lim, Young Jae ^g   Kijima, Yoshiyuki ^h   Koretsune, Yukihiro ⁱ   Nakatani, Daisaku ^a   Mizuno, Hiroya ^a   Shimizu, Masahiko ^a   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sakurabashi Watanabe Hospital   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

^d KANSAI ROSAI HOSPITAL   (Japan)

^e OSAKA GENERAL MEDICAL CENTER   (Japan)

^f OSAKA ROSAI HOSPITAL   (Japan)

^g KAWACHI GENERAL HOSPITAL   (Japan)

^h OSAKA CITY GENERAL HOSPITAL   (Japan)

ⁱ OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Myocardial infarction; Prevention; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC ACID DERIVATIVE; PRAVASTATIN; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFECT; DRUG UTILIZATION; EARLY INTERVENTION; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL READMISSION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RISK REDUCTION; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; HOSPITALIZATION; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME; UTILIZATION REVIEW;

AGED; ANGINA, UNSTABLE; DEATH; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PRAVASTATIN; RECURRENCE; STROKE; TREATMENT OUTCOME;

EID: 39849090518     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.17     Document Type: Article

References (31)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1308.
2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TEXCAPS (air Force/Texas Coronary Atherosclerosis Prevention Study). JAMA 1998; 279: 1615-1622.
3. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease Study G. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
6. Spencer FA. Allegrone J, Goldberg RJ, Gore JM, Fox KAA, Granger CB, et al. Association of statin therapy with outcomes of acute coronary syndromes: The Grace Study. Ann Intern Med 2004; 140: 857-866.
7. Arntz HR, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, et al. Beneficial effects of pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease [L-CAD] Study). Am J Cardiol 2000; 86: 1293-1298.
8. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
9. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL Study: A randomized controlled trial. JAMA 2001; 285: 1711-1718.
10. Thompson PL, Meredith I, Amerena J, Campbell TJ, Sloman JG, Harris PJ. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: The Pravastatin in Acute Coronary Treatment (PACT) Trial. Am Heart J 2004; 148: 91.
11. Kinjo K, Sato H, Ohnishi Y, Hishida E, Nakatani D, Mizuno H, et al. Impact of high-sensitivity C-reactive protein on predicting long-term mortality of acute myocardial infarction. Am J Cardiol 2003; 91: 931-935.
12. Kinjo K, Sato H, Sato H, Ohnishi Y, Hishida E, Nakatani D, et al. Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol 2003; 92: 1150-1154.
13. Ohnishi Y, Tanaka T, Yamada R, Suematsu K, Minami M, Fujii K, et al. Identification of 187 single nucleotide polymorphisms (SNPs) among 41 candidate genes for ischemic heart disease in the Japanese population. Hum Genet 2000; 106: 288-292.
14. Ozaki K, Inoue K, Sato H, Iida A, Ohnishi Y, Sekine A, et al. Functional variation in lgals2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. Nature 2004; 429: 72-75.
15. Sakata Y, Sato H, Kinjo K, Fujii K, Kodama K, Tanouchi J, et al. Rationale and design of the OACIS-LIPID study that evaluates early use of pravastatin in acute myocardial infarction. Heart Drug 2005; 5: 193-196.
16. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-1445.
17. Dupuis J, Tardif J-C, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) Trial. Circulation 1999; 99: 3227-3233.
18. Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 1999; 95: 229-234.
19. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057-2064.
20. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-436.
21. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study. Lancet 2001; 357: 1063-1068.
22. Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002; 287: 3087-3095.
23. Kinjo K, Sato H, Sakata Y, Nakatani D, Mizuno H, Shimizu M, et al. Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy. Am J Cardiol 2005; 96: 617-621.
24. Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG, et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: A randomized trial. Eur Heart J 2002; 23: 1931-1937.
25. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 2004; 30: 30.
26. Mulder HJ, Bal ET, Jukema JW, Zwinderman AH, Schalij MJ, van Boven AJ, et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (Regress Trial). Am J Cardiol 2000; 86: 742-746.
27. van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris: Regress study group. Circulation 1996; 94: 1503-1505.
28. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
29. Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, et al. A tale of two trials: A comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI22. Circulation 2006; 113: 1406-1414.
30. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (mega study): A prospective randomised controlled trial. Lancet 2006; 368: 1155-1163.
31. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 2006; 97: 1165-1171.